
Amdocal Pro 2.5 mg+5 m
Beximco Pharmaceuticals Ltd.
Bisoprolol Fumarate + Amlodipine Besilate is a fixed-dose combination antihypertensive indicated for the treatment of hypertension in adult patients who require combination therapy to achieve…
Bisoprolol Fumarate + Amlodipine Besilate is a fixed-dose combination antihypertensive indicated for the treatment of hypertension in adult patients who require combination therapy to achieve adequate blood pressure control.
Bisoprolol Fumarate + Amlodipine Besilate is not indicated for hypertensive emergencies, initial therapy in treatment-naive patients without prior assessment of individual component response, or as a substitute for lifestyle modification.
| Indication | Typical starting dose | Titration / maintenance |
|---|---|---|
| Essential hypertension requiring combination therapy | Lowest available strength of Bisoprolol Fumarate + Amlodipine Besilate once daily (e.g. bisoprolol 2.5 mg/amlodipine 5 mg equivalent, per locally marketed strengths) | May be titrated to a higher fixed-dose strength after 2-4 weeks based on individual blood pressure response and tolerability, up to the maximum strength marketed locally |
Amlodipine pharmacokinetics are not significantly altered by renal impairment; bisoprolol is partly renally eliminated, so in patients with significant renal impairment, dose initiation with the lowest strength and careful monitoring is recommended before considering Bisoprolol Fumarate + Amlodipine Besilate, or the individual components may need to be titrated separately first.
Amlodipine is extensively hepatically metabolized; in patients with hepatic impairment, slower titration and lower starting doses are recommended. Bisoprolol Fumarate + Amlodipine Besilate should be initiated cautiously, generally starting with the lowest available strength, in patients with hepatic impairment.
Side effects of Bisoprolol Fumarate + Amlodipine Besilate reflect the combined profiles of bisoprolol fumarate and amlodipine besilate.
Peripheral edema from the amlodipine component is dose-related and a common reason patients discontinue Bisoprolol Fumarate + Amlodipine Besilate; fatigue, dizziness, and bradycardia relate mainly to the bisoprolol component and are most prominent at treatment initiation or after dose increases.
Bisoprolol Fumarate + Amlodipine Besilate is contraindicated in patients with any of the following:
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.